Biomarkers and combination therapies using oncolytic virus and immunomodulation

Patent metadata

Field	Value
Publication number	US-10238698-B2
Application number	US-201314374619-A
Country	US
Kind code	B2
Filing date	Jan 25, 2013
Priority date	Jan 25, 2012
Publication date	Mar 26, 2019
Grant date	Mar 26, 2019

Abstract

The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

First claim

The invention claimed is:

1. A method for treating cancer in a patient having or suspected of having cancer comprising (a) administering a Delta-24 oncolytic adenovirus for a treatment period, (b) measuring the level of one or more Th1 biomarkers at a first time point and at a subsequent second time point, and (c) comparing the level of one or more Th1 biomarkers at the first time point and the second time point, wherein a decrease in one or more Th1 biomarkers at the second time point compared to the first time point indicates that the patient is non-responsive to treatment with the Delta-24 oncolytic adenovirus.

2. The method of claim 1 , further comprising administering a Th1 stimulating agent to the patient with the Delta-24 oncolytic adenovirus if the patient is determined to be non-responsive.

3. The method of claim 1 , wherein said Delta-24 oncolytic adenovirus is a Delta-24-RGD oncolytic adenovirus.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of primary brain cancer, metastatic brain cancer, lung cancer, breast cancer and prostate cancer.

5. The method of claim 4 , wherein the cancer is low-grade or high-grade glioma.

6. The method of claim 5 , wherein the cancer is high-grade glioma.

Assignees

• Dna Trix Inc
• Md Anderson Cancer Center
• Dnatrix Inc
• Univ Texas

Inventors

• Tufaro Frank
• Conrad Charles
• Fueyo-Margareto Juan
• Lang Jr Frederick
• Gomez-Manzano Candelaria
• Yung W K Alfred
• Heimberger Amy

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title